You are here

Professor Trevor Leong discusses TOPGEAR Trial at ECC, Vienna, 2015

Trevor Leong discuss TOPGEAR at ECC 2015

Professor Trevor Leong discusses a randomised trial, TOPGEAR (Trial Of Pre-operative therapy for Gastric and Esophagogastric junction AdenocaRcinoma), which compares pre-operative chemoradiation with pre-operative chemotherapy alone for patients with resectable gastric cancer. The background of this study is that currently the optimal adjuvant strategy for patients with gastric cancer is unknown. In Western countries there are two standards of care. There is either post-operative chemoradiotherapy or peri-operative chemotherapy using epirubicin/cisplatin/fluorouracil (ECF).

Chemoradiation in the pre-operative phase: TOPGEAR trial

This trial compares chemoradiation to chemotherapy alone in the adjuvant setting but with the advantage of bringing the chemoradiation in the pre-operative setting which has a lot of advantages compared to post-operative treatment. TOPGEAR is split in two parts: Part 1 to show the feasibility and safety and Part 2 to examine the overall survival as primary endpoint. Part 1 is the phase II component and will recruit 120 patients, while Part 2 is the phase III component that will involve further 632 patients to provide a total sample size of 752 patients.

Hematological and non-hematological toxicities in phase II

Part 1 of the TOPGEAR trial was completed in 2015. The safety profile shows very similar hematological and non-hematological toxicities between the chemoradiation and the chemotherapy arm. The study demonstrates particularly that the strategy with chemoradiation in the pre-operative setting doesn’t affect surgical compliance and surgical complications compared to control.


Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.